Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 383

1.

Factors Affecting the Tissue Damaging Consequences of Viral Infections.

Sumbria D, Berber E, Rouse BT.

Front Microbiol. 2019 Oct 4;10:2314. doi: 10.3389/fmicb.2019.02314. eCollection 2019. Review.

2.

The Role of T Cells in Herpes Stromal Keratitis.

Rajasagi NK, Rouse BT.

Front Immunol. 2019 Mar 19;10:512. doi: 10.3389/fimmu.2019.00512. eCollection 2019. Review.

3.

Gal power: the diverse roles of galectins in regulating viral infections.

Machala EA, McSharry BP, Rouse BT, Abendroth A, Slobedman B.

J Gen Virol. 2019 Mar;100(3):333-349. doi: 10.1099/jgv.0.001208. Epub 2019 Jan 16.

PMID:
30648945
4.

Role of IL-18 induced Amphiregulin expression on virus induced ocular lesions.

Varanasi SK, Rajasagi NK, Jaggi U, Rouse BT.

Mucosal Immunol. 2018 Nov;11(6):1705-1715. doi: 10.1038/s41385-018-0058-8. Epub 2018 Aug 7.

5.

Virological and Immunological Outcomes of Coinfections.

Kumar N, Sharma S, Barua S, Tripathi BN, Rouse BT.

Clin Microbiol Rev. 2018 Jul 5;31(4). pii: e00111-17. doi: 10.1128/CMR.00111-17. Print 2018 Oct. Review.

6.

Herpesviruses: Harmonious Pathogens but Relevant Cofactors in Other Diseases?

Sehrawat S, Kumar D, Rouse BT.

Front Cell Infect Microbiol. 2018 May 25;8:177. doi: 10.3389/fcimb.2018.00177. eCollection 2018. Review.

7.

On the role of retinoic acid in virus induced inflammatory response in cornea.

Jaggi U, Varanasi SK, Bhela S, Rouse BT.

Microbes Infect. 2018 Jun - Jul;20(6):337-345. doi: 10.1016/j.micinf.2018.04.007. Epub 2018 May 26.

PMID:
29842984
8.

Hexokinase II may be dispensable for CD4 T cell responses against a virus infection.

Varanasi SK, Jaggi U, Hay N, Rouse BT.

PLoS One. 2018 Jan 19;13(1):e0191533. doi: 10.1371/journal.pone.0191533. eCollection 2018.

9.

Application of our understanding of pathogenesis of herpetic stromal keratitis for novel therapy.

Rajasagi NK, Rouse BT.

Microbes Infect. 2018 Oct - Nov;20(9-10):526-530. doi: 10.1016/j.micinf.2017.12.014. Epub 2018 Jan 9. Review.

10.

Are miRNAs critical determinants in herpes simplex virus pathogenesis?

Bhela S, Rouse BT.

Microbes Infect. 2018 Oct - Nov;20(9-10):461-465. doi: 10.1016/j.micinf.2017.12.007. Epub 2017 Dec 26. Review.

11.

How host metabolism impacts on virus pathogenesis.

Varanasi SK, Rouse BT.

Curr Opin Virol. 2018 Feb;28:37-42. doi: 10.1016/j.coviro.2017.11.003. Epub 2017 Nov 16. Review. No abstract available.

PMID:
29156318
12.

miR-31: a key player in CD8 T-cell exhaustion.

Bhela S, Rouse BT.

Cell Mol Immunol. 2017 Dec;14(12):954-956. doi: 10.1038/cmi.2017.89. Epub 2017 Sep 11. No abstract available.

13.

Manipulating Glucose Metabolism during Different Stages of Viral Pathogenesis Can Have either Detrimental or Beneficial Effects.

Varanasi SK, Donohoe D, Jaggi U, Rouse BT.

J Immunol. 2017 Sep 1;199(5):1748-1761. doi: 10.4049/jimmunol.1700472. Epub 2017 Aug 2.

14.

The Plasticity and Stability of Regulatory T Cells during Viral-Induced Inflammatory Lesions.

Bhela S, Varanasi SK, Jaggi U, Sloan SS, Rajasagi NK, Rouse BT.

J Immunol. 2017 Aug 15;199(4):1342-1352. doi: 10.4049/jimmunol.1700520. Epub 2017 Jul 14.

15.

Frontline Science: Aspirin-triggered resolvin D1 controls herpes simplex virus-induced corneal immunopathology.

Rajasagi NK, Bhela S, Varanasi SK, Rouse BT.

J Leukoc Biol. 2017 Nov;102(5):1159-1171. doi: 10.1189/jlb.3HI1216-511RR. Epub 2017 Jun 5.

16.

Interplay of Regulatory T Cell and Th17 Cells during Infectious Diseases in Humans and Animals.

Sehrawat S, Rouse BT.

Front Immunol. 2017 Apr 3;8:341. doi: 10.3389/fimmu.2017.00341. eCollection 2017. Review.

17.

Azacytidine Treatment Inhibits the Progression of Herpes Stromal Keratitis by Enhancing Regulatory T Cell Function.

Varanasi SK, Reddy PBJ, Bhela S, Jaggi U, Gimenez F, Rouse BT.

J Virol. 2017 Mar 13;91(7). pii: e02367-16. doi: 10.1128/JVI.02367-16. Print 2017 Apr 1.

18.

DNA Vaccines - A Modern Gimmick or a Boon to Vaccinology?

Manickan E, Karem KL, Rouse BT.

Crit Rev Immunol. 2017;37(2-6):483-498. doi: 10.1615/CritRevImmunol.v37.i2-6.140. Review.

PMID:
29773031
19.

IL-2 complex treatment amplifies CD8+ T cell mediated immunity following herpes simplex virus-1 infection.

Rajasagi NK, Rouse BT.

Microbes Infect. 2016 Dec;18(12):735-746. doi: 10.1016/j.micinf.2016.10.010. Epub 2016 Nov 17.

20.

Some vexations that challenge viral immunology.

Rouse BT, Mueller SN.

F1000Res. 2016 May 27;5. pii: F1000 Faculty Rev-1015. doi: 10.12688/f1000research.8391.1. eCollection 2016. Review.

21.

Robo 4 Counteracts Angiogenesis in Herpetic Stromal Keratitis.

Gimenez F, Mulik S, Veiga-Parga T, Bhela S, Rouse BT.

PLoS One. 2015 Dec 31;10(12):e0141925. doi: 10.1371/journal.pone.0141925. eCollection 2015.

22.

The inflammasome NLRP3 plays a protective role against a viral immunopathological lesion.

Gimenez F, Bhela S, Dogra P, Harvey L, Varanasi SK, Jaggi U, Rouse BT.

J Leukoc Biol. 2016 May;99(5):647-57. doi: 10.1189/jlb.3HI0715-321R. Epub 2015 Oct 29.

23.

Role of miR-155 in the pathogenesis of herpetic stromal keratitis.

Bhela S, Mulik S, Gimenez F, Reddy PB, Richardson RL, Varanasi SK, Jaggi U, Xu J, Lu PY, Rouse BT.

Am J Pathol. 2015 Apr;185(4):1073-84. doi: 10.1016/j.ajpath.2014.12.021. Epub 2015 Feb 18.

24.

Herpes virus entry mediator (HVEM) modulates proliferation and activation of regulatory T cells following HSV-1 infection.

Sharma S, Rajasagi NK, Veiga-Parga T, Rouse BT.

Microbes Infect. 2014 Aug;16(8):648-60. doi: 10.1016/j.micinf.2014.06.005. Epub 2014 Jun 21.

25.

An approach to control relapse of inflammatory lesions after discontinuation of primary therapy.

Reddy PB, Sehrawat S, Suryawanshi A, Rajasagi NK, Khatri M, Rouse BT.

PLoS One. 2014 May 20;9(5):e98051. doi: 10.1371/journal.pone.0098051. eCollection 2014.

26.

Critical role of microRNA-155 in herpes simplex encephalitis.

Bhela S, Mulik S, Reddy PB, Richardson RL, Gimenez F, Rajasagi NK, Veiga-Parga T, Osmand AP, Rouse BT.

J Immunol. 2014 Mar 15;192(6):2734-43. doi: 10.4049/jimmunol.1302326. Epub 2014 Feb 10.

27.

Role of regulatory T cells during virus infection.

Veiga-Parga T, Sehrawat S, Rouse BT.

Immunol Rev. 2013 Sep;255(1):182-96. doi: 10.1111/imr.12085. Review.

28.

Neuroprotectin D1 reduces the severity of herpes simplex virus-induced corneal immunopathology.

Rajasagi NK, Reddy PB, Mulik S, Gjorstrup P, Rouse BT.

Invest Ophthalmol Vis Sci. 2013 Sep 17;54(9):6269-79. doi: 10.1167/iovs.13-12152.

29.

Controlling herpetic stromal keratitis by modulating lymphotoxin-alpha-mediated inflammatory pathways.

Veiga-Parga T, Giménez F, Mulik S, Chiang EY, Grogan JL, Rouse BT.

Microbes Infect. 2013 Sep-Oct;15(10-11):677-87. doi: 10.1016/j.micinf.2013.07.001. Epub 2013 Jul 10.

30.

Potential function of miRNAs in herpetic stromal keratitis.

Mulik S, Bhela S, Rouse BT.

Invest Ophthalmol Vis Sci. 2013 Jan 17;54(1):563-73. doi: 10.1167/iovs.12-11094. Review.

31.

On the role of regulatory T cells during viral-induced inflammatory lesions.

Veiga-Parga T, Suryawanshi A, Mulik S, Giménez F, Sharma S, Sparwasser T, Rouse BT.

J Immunol. 2012 Dec 15;189(12):5924-33. doi: 10.4049/jimmunol.1202322. Epub 2012 Nov 5.

32.

Pathogenesis of herpes stromal keratitis--a focus on corneal neovascularization.

Giménez F, Suryawanshi A, Rouse BT.

Prog Retin Eye Res. 2013 Mar;33:1-9. doi: 10.1016/j.preteyeres.2012.07.002. Epub 2012 Aug 7. Review.

33.

TNFRSF25 agonistic antibody and galectin-9 combination therapy controls herpes simplex virus-induced immunoinflammatory lesions.

J Reddy PB, Schreiber TH, Rajasagi NK, Suryawanshi A, Mulik S, Veiga-Parga T, Niki T, Hirashima M, Podack ER, Rouse BT.

J Virol. 2012 Oct;86(19):10606-20. doi: 10.1128/JVI.01391-12. Epub 2012 Jul 18.

34.

Role of miR-132 in angiogenesis after ocular infection with herpes simplex virus.

Mulik S, Xu J, Reddy PB, Rajasagi NK, Gimenez F, Sharma S, Lu PY, Rouse BT.

Am J Pathol. 2012 Aug;181(2):525-34. doi: 10.1016/j.ajpath.2012.04.014. Epub 2012 May 31.

35.

Galectin-1 reduces the severity of herpes simplex virus-induced ocular immunopathological lesions.

Rajasagi NK, Suryawanshi A, Sehrawat S, Reddy PB, Mulik S, Hirashima M, Rouse BT.

J Immunol. 2012 May 1;188(9):4631-43. doi: 10.4049/jimmunol.1103063. Epub 2012 Mar 30.

36.

IL-17A differentially regulates corneal vascular endothelial growth factor (VEGF)-A and soluble VEGF receptor 1 expression and promotes corneal angiogenesis after herpes simplex virus infection.

Suryawanshi A, Veiga-Parga T, Reddy PB, Rajasagi NK, Rouse BT.

J Immunol. 2012 Apr 1;188(7):3434-46. doi: 10.4049/jimmunol.1102602. Epub 2012 Feb 29.

37.

Emerged HA and NA mutants of the pandemic influenza H1N1 viruses with increasing epidemiological significance in Taipei and Kaohsiung, Taiwan, 2009-10.

Kao CL, Chan TC, Tsai CH, Chu KY, Chuang SF, Lee CC, Li ZR, Wu KW, Chang LY, Shen YH, Huang LM, Lee PI, Yang C, Compans R, Rouse BT, King CC.

PLoS One. 2012;7(2):e31162. doi: 10.1371/journal.pone.0031162. Epub 2012 Feb 6.

38.

Controlling viral immuno-inflammatory lesions by modulating aryl hydrocarbon receptor signaling.

Veiga-Parga T, Suryawanshi A, Rouse BT.

PLoS Pathog. 2011 Dec;7(12):e1002427. doi: 10.1371/journal.ppat.1002427. Epub 2011 Dec 8.

39.

T cell immunoglobulin and mucin protein-3 (Tim-3)/Galectin-9 interaction regulates influenza A virus-specific humoral and CD8 T-cell responses.

Sharma S, Sundararajan A, Suryawanshi A, Kumar N, Veiga-Parga T, Kuchroo VK, Thomas PG, Sangster MY, Rouse BT.

Proc Natl Acad Sci U S A. 2011 Nov 22;108(47):19001-6. doi: 10.1073/pnas.1107087108. Epub 2011 Nov 3.

40.

Influence of galectin-9/Tim-3 interaction on herpes simplex virus-1 latency.

Reddy PB, Sehrawat S, Suryawanshi A, Rajasagi NK, Mulik S, Hirashima M, Rouse BT.

J Immunol. 2011 Dec 1;187(11):5745-55. doi: 10.4049/jimmunol.1102105. Epub 2011 Oct 21.

41.

Tregs and infections: on the potential value of modifying their function.

Sehrawat S, Rouse BT.

J Leukoc Biol. 2011 Dec;90(6):1079-87. doi: 10.1189/jlb.0611271. Epub 2011 Sep 13. Review.

42.

Role of IL-17 and Th17 cells in herpes simplex virus-induced corneal immunopathology.

Suryawanshi A, Veiga-Parga T, Rajasagi NK, Reddy PB, Sehrawat S, Sharma S, Rouse BT.

J Immunol. 2011 Aug 15;187(4):1919-30. doi: 10.4049/jimmunol.1100736. Epub 2011 Jul 15.

43.

Consensus statement on indications for anti-angiogenic therapy in the management of corneal diseases associated with neovascularisation: outcome of an expert roundtable.

Cursiefen C, Colin J, Dana R, Diaz-Llopis M, Faraj LA, Garcia-Delpech S, Geerling G, Price FW, Remeijer L, Rouse BT, Seitz B, Udaondo P, Meller D, Dua H.

Br J Ophthalmol. 2012 Jan;96(1):3-9. doi: 10.1136/bjo.2011.204701. Epub 2011 Jun 28.

PMID:
21712359
44.

Activation of endothelial roundabout receptor 4 reduces the severity of virus-induced keratitis.

Mulik S, Sharma S, Suryawanshi A, Veiga-Parga T, Reddy PB, Rajasagi NK, Rouse BT.

J Immunol. 2011 Jun 15;186(12):7195-204. doi: 10.4049/jimmunol.1100014. Epub 2011 May 13.

45.

An anti-inflammatory role of VEGFR2/Src kinase inhibitor in herpes simplex virus 1-induced immunopathology.

Sharma S, Mulik S, Kumar N, Suryawanshi A, Rouse BT.

J Virol. 2011 Jun;85(12):5995-6007. doi: 10.1128/JVI.00034-11. Epub 2011 Apr 6.

46.

Immunopathological aspects of HSV infection.

Banerjee K, Rouse BT.

In: Arvin A, Campadelli-Fiume G, Mocarski E, Moore PS, Roizman B, Whitley R, Yamanishi K, editors. Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. Cambridge: Cambridge University Press; 2007. Chapter 35.

47.

Ocular neovascularization caused by herpes simplex virus type 1 infection results from breakdown of binding between vascular endothelial growth factor A and its soluble receptor.

Suryawanshi A, Mulik S, Sharma S, Reddy PB, Sehrawat S, Rouse BT.

J Immunol. 2011 Mar 15;186(6):3653-65. doi: 10.4049/jimmunol.1003239. Epub 2011 Feb 16.

48.

Macrophage IL-12p70 signaling prevents HSV-1-induced CNS autoimmunity triggered by autoaggressive CD4+ Tregs.

Mott KR, Gate D, Zandian M, Allen SJ, Rajasagi NK, van Rooijen N, Chen S, Arditi M, Rouse BT, Flavell RA, Town T, Ghiasi H.

Invest Ophthalmol Vis Sci. 2011 Apr 8;52(5):2321-33. doi: 10.1167/iovs.10-6536. Print 2011 Apr.

49.

Controlling herpes simplex virus-induced ocular inflammatory lesions with the lipid-derived mediator resolvin E1.

Rajasagi NK, Reddy PB, Suryawanshi A, Mulik S, Gjorstrup P, Rouse BT.

J Immunol. 2011 Feb 1;186(3):1735-46. doi: 10.4049/jimmunol.1003456. Epub 2010 Dec 27.

50.

Some unmet challenges in the immunology of viral infections.

Rouse BT, Lukacher AE.

Discov Med. 2010 Oct;10(53):363-70. Review.

Supplemental Content

Loading ...
Support Center